Literature DB >> 11170190

Treatment of intrinsic sphincter deficiency using autologous ear chondrocytes as a bulking agent.

A E Bent1, R T Tutrone, M T McLennan, L K Lloyd, M J Kennelly, G Badlani.   

Abstract

Intrinsic sphincter deficiency (ISD) is frequently treated with collagen bulking at the bladder neck. The standard material used, Contigen, biodegrades over 3-19 months requiring repeated injections to maintain efficacy. The study objective was to evaluate use of autologous ear chondrocytes for treatment of ISD. Women with documented ISD had harvest of auricular cartilage. Chondrocytes were isolated from the cartilage and expanded in culture and formulated with calcium alginate to form an injectable gel. Thirty-two patients received a single outpatient injection just distal to the bladder neck. Outcome measures included voiding diary, quality-of-life scores, incontinence severity grading, and pad weight testing. Incontinence grading indicated 16 patients dry, and 10 improved at 12 months for a total of 26 of 32 (81.3%) dry and improved after one treatment. Only four patients had a 12-month pad weight test over 2.2 g. Quality-of-life scores improved significantly after treatment. There was a decrease in incontinence impact scores in all categories. The urogenital distress inventory declined for all categories except bladder emptying and lower abdominal pain. Endoscopic treatment of ISD with autologous chondrocytes is safe, effective, and durable with 50 % of patients dry 12 months after one injection. Twenty-six of 32 patients dry or improved at 3 months after the injection maintained the effect at the 12-month visit. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11170190     DOI: 10.1002/1520-6777(2001)20:2<157::aid-nau18>3.0.co;2-a

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  18 in total

Review 1.  Challenges in tissue engineering.

Authors:  Yoshito Ikada
Journal:  J R Soc Interface       Date:  2006-10-22       Impact factor: 4.118

2.  Current use of injectable agents for female stress urinary incontinence.

Authors:  Sender Herschorn
Journal:  Rev Urol       Date:  2005

3.  Advances in the understanding of sress urinary incontinence and the promise of stem-cell therapy.

Authors:  Akira Furuta; Lesley K Carr; Naoki Yoshimura; Michael B Chancellor
Journal:  Rev Urol       Date:  2007

Review 4.  The promise of stem cell therapy to restore urethral sphincter function.

Authors:  Akira Furuta; Ron J Jankowski; Ryan Pruchnic; Naoki Yoshimura; Michael B Chancellor
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

Review 5.  Treatment options for intrinsic sphincter deficiency.

Authors:  Sovrin M Shah; Geoffrey S Gaunay
Journal:  Nat Rev Urol       Date:  2012-10-02       Impact factor: 14.432

6.  Refilling drug delivery depots through the blood.

Authors:  Yevgeny Brudno; Eduardo A Silva; Cathal J Kearney; Sarah A Lewin; Alex Miller; Kathleen D Martinick; Michael Aizenberg; David J Mooney
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-19       Impact factor: 11.205

Review 7.  Management of recurrent stress incontinence following a sling.

Authors:  Geneviève Nadeau; Sender Herschorn
Journal:  Curr Urol Rep       Date:  2014-08       Impact factor: 3.092

8.  Where should bulking agents for female urodynamic stress incontinence be injected?

Authors:  Annette Kuhn; Werner Stadlmayr; Daniela Lengsfeld; Michel D Mueller
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-06

9.  Long-term results and patients' satisfaction after transurethral ethylene vinyl alcohol (Tegress) injections: a two-centre study.

Authors:  Annette Kuhn; Werner Stadlmayr; Amara Sohail; Ash Monga
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-10-23

Review 10.  Stress urinary incontinence in women.

Authors:  Pejvak Sassani; Sherif R Aboseif
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.